Trial Profile
A multiple dose, double-blind, double-dummy, 3 period cross-over, placebo controlled clinical trial to assess the efficacy and safety of once daily inhaled aclidinium bromide 200 microg given either in the morning or in the evening in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jul 2019
Price :
$35
*
At a glance
- Drugs Aclidinium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Almirall S.A.
- 30 Jul 2011 New trial record
- 10 May 2011 The trial status is completed in Germany and is discontinued in United Kingdom.